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233“responders,” deﬁned as a reduction in ambulatory
systolic blood pressure (SBP) of >10 mm Hg, it ap-
pears crucial to ascertain whether the BP reduction
following RDN parallels BRS improvement in these
patients. This is even more important in view of
recent ﬁndings demonstrating that baroreﬂex func-
tion consistently improves after RDN in hypertensive
rats and humans, even if BP is not improved (2). In
this context, it is noteworthy that similar to previous
studies (3,4), baseline BP also emerged as an impor-
tant determinant of the BP response to RDN in this
analysis.
The methodology applied by the authors may raise
some concern. In contrast to the commonly used
application of the sequence method for the assess-
ment of BRS described by Parati et al. (5), sponta-
neous sequence of BRS in this study was estimated
only during the progressive increase of SBP over 3 or
more consecutive beats in which RR intervals are
simultaneously prolonged, but not when SBP pro-
gressively falls and cardiac intervals are progressively
shortened. Additionally, assessment of baroreﬂex
control of heart rate is to a large extent driven by
vagal inﬂuences, not necessarily by the sympathetic
nervous system, although the opposite is frequently
quoted in the literature (6). Nevertheless, our own
ﬁndings from more than 100 patients with resistant
hypertension indicate that these patients are typi-
cally characterized by very high levels of muscle
sympathetic nerve activity, with RDN resulting in
sympathetic inhibition in most. In this context, it will
be important to assess whether spontaneous arterial
baroreﬂex control of muscle sympathetic nerve ac-
tivity may be an even better predictor of the BP
response to RDN. It should also be noted that,
although established hypertension is associated with
impaired baroreﬂex function, the role of baroreﬂex
control in long-term regulation of BP is more
disputable and has not yet been fully elucidated.Dagmara Hering, MD, PhD
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Auton Res 2003;13:170–2.REPLY: Baroreﬂex Sensitivity: A Reliable
Predictor of Response to Renal Denervation?We appreciate the interest in our paper (1) and the
opportunity to reply to the thoughtful comments by
Dr. Hering and colleagues.
We agree that testing the effect of renal sympa-
thetic denervation (RDN) on cardiac baroreﬂex
sensitivity (BRS) would provide important insights
into the mechanistic basis of RDN. However, this was
not the objective of our study (1). The primary goal
of our clinical study was to prospectively identify
patients with resistant hypertension who would
eventually beneﬁt from RDN. We showed in 50 hy-
pertensive patients that impaired cardiac BRS was a
strong and independent predictor of blood pressure
(BP) reduction after RDN.
Dr. Hering and colleagues speculated that RDN
should lead to BRS improvement only in patients who
beneﬁt from RDN in terms of BP reduction. Their
interesting hypothesis was on the basis of physio-
logical considerations as well as on a recent study in
7 hypertensive rats and 8 hypertensive human pa-
tients, which investigated the effects of RDN on BP,
muscle sympathetic nerve activity (MSNA), and BRS
(2). In that study, rats consistently showed signiﬁcant
reductions of BP and MSNA as well as improvements
of BRS, whereas in humans, no signiﬁcant effects
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234on BP and MSNA were noted. Interestingly, RDN
resulted in signiﬁcant improvement of BRS in
humans, which, however, did not parallel BP
changes. In our opinion, a differential effect of RDN
on BRS in responders and nonresponders, although
intriguing, cannot be derived from these data. Lack of
evidence of a differential bidirectional relationship
between BRS and BP response does not question the
results of our study.
Dr. Hering and colleagues also mentioned the
methodology of BRS assessment. In our study, we
used mainly phase-rectiﬁed signal averaging (PRSA)
to obtain an estimate of spontaneous cardiac BRS
(BRSPRSA). We have previously shown that BRSPRSA
provides both methodological and prognostic ad-
vantages over standard methods of BRS assessment,
including the sequence method (3,4). We agree that
cardiac BRS is an integral autonomic marker that is
inﬂuenced by both vagal and sympathetic effects.
Whether baroreﬂex control of muscle sympathetic
nerve activity might be a better predictor of re-
sponse to RDN is speculative. For clinical purposes,
however, such an approach would be highly im-
practicable as this technique requires invasive
neural recordings that can only be performed in
specialized centers.Christine S. Zuern, MD
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